

Table 2: Secondary visual acuity outcomes at 12 months

Secondary outcome measure	Epimacular brachytherapy (n)	Ranibizumab monotherapy	P
Proportion losing ≤ 15 letters	84% (204)	92% (110)	0.007
Proportion gaining ≥ 0 letters	37% (91)	46% (55)	0.073
Proportion gaining ≥ 15 letters	1% (3)	5% (6)	0.058